Rectal Cancer Stage III Clinical Trial
Official title:
Using CNN Image Recognition to Predict Rectal Cancer Outcomes
NCT number | NCT05723965 |
Other study ID # | CE21235B |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 1, 2010 |
Est. completion date | December 31, 2022 |
Verified date | February 2023 |
Source | Taichung Veterans General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Investigator retrospective collect cases during 2010-2021 diagnosed as rectal adenocarcinoma with high quality CT images. Local advanced rectal cancer cases were labeled as "disease". Nor were defined " normal". Using artificial intelligence CNN on jupyter notebook with open phyton code to train and develop models capable to recognizing local advanced rectal cancer. Modify the phyton code for better predict rate and help physician to quickly evaluate disease severity for fresh rectal cancer cases.
Status | Completed |
Enrollment | 720 |
Est. completion date | December 31, 2022 |
Est. primary completion date | July 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 100 Years |
Eligibility | Inclusion Criteria: - clinical staging T3-4 with high quality CT images. Exclusion Criteria: - 1. not primary malignancy lesion - 2. not localizing rectum - 3. T1-2 lesion - 4. non contrast or poor quality images |
Country | Name | City | State |
---|---|---|---|
Taiwan | Taichung Verterans General Hospital | Taichung |
Lead Sponsor | Collaborator |
---|---|
Taichung Veterans General Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | accuracy of artificial intelligence with experienced physician | accuracy between artificial intelligence and experienced physician | 1 week after images done. | |
Secondary | real life survival outcome of diagnosis by artificial intelligence. | real life survival outcome by artificial intelligence. | 5 years after diagnosed |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05495308 -
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
|
||
Recruiting |
NCT04598984 -
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
|
||
Active, not recruiting |
NCT04246684 -
Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients
|
Phase 3 | |
Not yet recruiting |
NCT05830890 -
Sentinel Lymph Node Biopsy in Rectal Cancer
|
N/A | |
Active, not recruiting |
NCT04503694 -
Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer
|
Phase 2 | |
Completed |
NCT02363374 -
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT03561142 -
Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy.
|
Phase 2 | |
Completed |
NCT03602079 -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
Phase 1/Phase 2 | |
Recruiting |
NCT05148767 -
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
|
Phase 4 | |
Recruiting |
NCT06254521 -
The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer
|
Phase 2 | |
Completed |
NCT01325649 -
Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma
|
N/A | |
Recruiting |
NCT04970498 -
Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
|
||
Active, not recruiting |
NCT03840239 -
TNT to Increase the Clinical Complete Response Rate for Distal LARC
|
Phase 2 | |
Active, not recruiting |
NCT03391843 -
Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer
|
Phase 2 |